May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Development of a New Preservative Free Formulation for the Treatment of Dry Eye Syndrome
Author Affiliations & Notes
  • R. Herrero–Vanrell
    School of Pharmacy. Complutense University, Madrid, Spain
    Department of Pharmacy and Pharmaceutical Technology,
  • M. Vicario
    School of Pharmacy. Complutense University, Madrid, Spain
    Department of Pharmacy and Pharmaceutical Technology,
  • E. Vico
    Department of Ophthalmology, Hospital Universitario San Carlos, Madrid, Spain
  • B. de las Heras
    School of Pharmacy. Complutense University, Madrid, Spain
    Department of Pharmacology,
  • J.M. Benitez del Castillo
    Department of Ophthalmology, Hospital Universitario San Carlos, Madrid, Spain
  • I.T. Molina–Martinez
    School of Pharmacy. Complutense University, Madrid, Spain
    Department of Pharmacy and Pharmaceutical Technology,
  • Footnotes
    Commercial Relationships  R. Herrero–Vanrell, None; M. Vicario, None; E. Vico, None; B. de las Heras, None; J.M. Benitez del Castillo, None; I.T. Molina–Martinez, None.
  • Footnotes
    Support  FIS (PI030910 HIGHWIRE EXLINK_ID="47:5:5585:1" VALUE="PI030910" TYPEGUESS="GEN" /HIGHWIRE ), FIS (PI030792 HIGHWIRE EXLINK_ID="47:5:5585:2" VALUE="PI030792" TYPEGUESS="GEN" /HIGHWIRE ), Redes Temáticas de Investigación Colaborativa (Subproyecto Superficie Ocular) and SAF (2004–06119–C02).
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5585. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Herrero–Vanrell, M. Vicario, E. Vico, B. de las Heras, J.M. Benitez del Castillo, I.T. Molina–Martinez; Development of a New Preservative Free Formulation for the Treatment of Dry Eye Syndrome . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5585.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Dry eye syndrome can be considered a group of diseases related to tear film disorders. Evaporative dry eye is one of the most frequent causes of this condition. The lipid layer plays a major role in avoiding the evaporation of the aqueous components of the ocular surface. Treatments directed to replace a disturbed lipid layer may have therapeutic benefits for dry eye patients. These formulations might contain lipid and aqueous components. Moreover these constituents must present film–forming properties. The aim of this work is to evaluate a new formulation destined to topical administration for dry eye syndrome.

Methods: : A preservative free formulation containing aqueous and lipid constituents was prepared. The lipid components were phosphatidylcholine derivatives and chlolesterol in a ratio of 8:1 and they were suspended in an aqueous solution of trehalose. The final concentration of lipids was 25mg/ml. Size of the lipid droplets and in–vitro properties of the solutions such as, surface tension, osmolarity, and pH were evaluated.

Results: : Formulations including phosphatidylcholine and cholesterol in aqueous solution (25mg/ml) resulted in a surface tension value of 25.5 (± 0.3) mN/m. The final solution was hypotonic with a pH value of 7.04 (± 0.5). The sizes of the lipids vesicles were smaller than 1µm (392nm–478.5nm). Particles higher than 1µm were practically absent in the formulation (<2%).

Conclusions: : The free preservative formulation presents good characteristics to be employed as a tear film substitute.

Keywords: cornea: tears/tear film/dry eye • pharmacology • conjunctiva 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×